本論文選擇以系統生物學的工具探討神經保護中藥作用機轉實 質，主要是為了克服傳統研究方法局限在單點或單一機轉的限制，從一 個廣泛性的角度，來聯結一個藥物所具有的各種不同藥效之間的關係。
在銀杏萃取物的作用機轉研究中，探討當銀杏當作保健食品服用時，對 正常腦部的基因表現影響，其中 neuroactive ligand-receptor interaction 路 徑為銀杏在大腦中重要的調控路徑，在此路徑 amine 受體中的多巴胺受 體為主要調控對象，研究中並發現銀杏對腦部及腎臟的調控基因大不相 同。在丹皮酚的作用機轉研究中，探討神經細胞暴露在氧化壓力環境 時，丹皮酚所造成基因表現改變的整體影響，這些丹皮酚所調控的差異 表達基因勾繪出丹皮酚的抗氧化、抗發炎、及對神經相關基因的影響可 能是經由 NF-κB活性而得來，而與 NF-κB相關的 APP 抑制讓丹皮酚有
潛力成為一個預防Aβ產生的藥物。
研究的結果為銀杏及牡丹皮提供了作用機轉的基礎，丹皮酚能抑制 APP 的表現及銀杏對多巴胺受體的作用為牡丹皮及銀杏提供藥物新作 用的可能性，以供臨床上對銀杏在多巴胺缺乏疾病或是牡丹皮在氧化壓 力引起的相關神經學病變的應用。展望今後，除了對更多的神經保護藥 物進行實質作用探討外，中藥複方的神經保護作用也應有計畫的進行療 效分析，以期建立中醫藥神經保護作用更完備的臨床應用基礎。
參考文獻
1. Mantz J, Degos V, Laigle C. Recent advances in pharmacologic neuroprotection. Eur J Anaesthesiol. 2010;27:6-10.
2. Mahadevan S, Park Y. Multifaceted therapeutic benefits of Ginkgo biloba L.: chemistry, efficacy, safety, and uses. J Food Sci.
2008;73:R14-19.
3. Luo Y. Alzheimer's disease, the nematode Caenorhabditis elegans, and ginkgo biloba leaf extract. Life Sci. 2006;78:2066-2072.
4. Hsieh CL, Cheng CY, Tsai TH, Lin IH, Liu CH, Chiang SY, Lin JG, Lao CJ, Tang NY. Paeonol reduced cerebral infarction involving the superoxide anion and microglia activation in ischemia-reperfusion injured rats. J Ethnopharmacol. 2006;106:208-215.
5. Watanabe CM, Wolffram S, Ader P, Rimbach G, Packer L, Maguire JJ, Schultz PG, Gohil K. The in vivo neuromodulatory effects of the herbal medicine ginkgo biloba. Proc Natl Acad Sci U S A.
2001;98:6577-6580.
6. Smith JV, Luo Y. Studies on molecular mechanisms of Ginkgo biloba extract. Appl Microbiol Biotechnol. 2004;64:465-472.
7. Li W, Trovero F, Cordier J, Wang Y, Drieu K, Papadopoulos V.
Prenatal exposure of rats to Ginkgo biloba extract (EGb 761) increases neuronal survival/growth and alters gene expression in the developing fetal hippocampus. Brain Res Dev Brain Res. 2003;144:169-180.
8. Toussaint O, Fuchs SY, Ronai ZA, Isoyama S, Yuko N, Petronilli V, Bernardi P, Gonos ES, Dumont P, Remacle J. Reciprocal relationships between the resistance to stresses and cellular aging. Ann N Y Acad Sci.
1998;851:450-465.
9. Golden TR, Hinerfeld DA, Melov S. Oxidative stress and aging:
beyond correlation. Aging Cell. 2002;1:117-123.
10. Haripriya D, Sangeetha P, Kanchana A, Balu M, Panneerselvam C.
Modulation of age-associated oxidative DNA damage in rat brain cerebral cortex, striatum and hippocampus by L-carnitine. Exp Gerontol. 2005;40:129-135.
11. Sohal RS. Role of oxidative stress and protein oxidation in the aging process. Free Radic Biol Med. 2002;33:37-44.
12. Berlett BS, Stadtman ER. Protein oxidation in aging, disease, and oxidative stress. J Biol Chem. 1997;272:20313-20316.
13. Bogdanov MB, Ramos LE, Xu Z, Beal MF. Elevated "hydroxyl radical" generation in vivo in an animal model of amyotrophic lateral sclerosis. J Neurochem. 1998;71:1321-1324.
14. Cookson MR, Shaw PJ. Oxidative stress and motor neurone disease.
Brain Pathol. 1999;9:165-186.
15. Gloire G, Legrand-Poels S, Piette J. NF-kappaB activation by reactive oxygen species: fifteen years later. Biochem Pharmacol.
2006;72:1493-1505.
16. Smith MA, Harris PL, Sayre LM, Perry G. Iron accumulation in Alzheimer disease is a source of redox-generated free radicals. Proc Natl Acad Sci U S A. 1997;94:9866-9868.
17. Kim S, Iwao H. Stress and vascular responses: mitogen-activated protein kinases and activator protein-1 as promising therapeutic targets of vascular remodeling. J Pharmacol Sci. 2003;91:177-181.
Kietzmann T, Gorlach A. Reactive oxygen species activate the HIF-1alpha promoter via a functional NFkappaB site. Arterioscler Thromb Vasc Biol. 2007;27:755-761.
19. Vajda FJ. Neuroprotection and neurodegenerative disease. J Clin Neurosci. 2002;9:4-8.
20. Nicotera P, Lipton SA. Excitotoxins in neuronal apoptosis and necrosis. J Cereb Blood Flow Metab. 1999;19:583-591.
21. Wang Q, Tang XN, Yenari MA. The inflammatory response in stroke.
J Neuroimmunol. 2007;184:53-68.
22. Emsley HC, Tyrrell PJ. Inflammation and infection in clinical stroke. J Cereb Blood Flow Metab. 2002;22:1399-1419.
23. DeGraba TJ. The role of inflammation after acute stroke: utility of pursuing anti-adhesion molecule therapy. Neurology. 1998;51:S62-68.
24. Han HS, Yenari MA. Cellular targets of brain inflammation in stroke.
Curr Opin Investig Drugs. 2003;4:522-529.
25. Allan SM, Rothwell NJ. Cytokines and acute neurodegeneration. Nat Rev Neurosci. 2001;2:734-744.
26. Chen Y, Hallenbeck JM, Ruetzler C, Bol D, Thomas K, Berman NE, Vogel SN. Overexpression of monocyte chemoattractant protein 1 in the brain exacerbates ischemic brain injury and is associated with recruitment of inflammatory cells. J Cereb Blood Flow Metab.
2003;23:748-755.
27. Glass CK, Saijo K, Winner B, Marchetto MC, Gage FH. Mechanisms underlying inflammation in neurodegeneration. Cell. 2010;140:918-934.
NR, Eikelenboom P, Emmerling M, Fiebich BL, Finch CE, Frautschy S, Griffin WS, Hampel H, Hull M, Landreth G, Lue L, Mrak R, Mackenzie IR, McGeer PL, O'Banion MK, Pachter J, Pasinetti G, Plata-Salaman C, Rogers J, Rydel R, Shen Y, Streit W, Strohmeyer R, Tooyoma I, Van Muiswinkel FL, Veerhuis R, Walker D, Webster S, Wegrzyniak B, Wenk G, Wyss-Coray T. Inflammation and Alzheimer's disease. Neurobiol Aging. 2000;21:383-421.
29. Kitazawa M, Yamasaki TR, LaFerla FM. Microglia as a potential bridge between the amyloid beta-peptide and tau. Ann N Y Acad Sci.
2004;1035:85-103.
30. Cartier L, Hartley O, Dubois-Dauphin M, Krause KH. Chemokine receptors in the central nervous system: role in brain inflammation and neurodegenerative diseases. Brain Res Brain Res Rev. 2005;48:16-42.
31. McGeer PL, Itagaki S, Boyes BE, McGeer EG. Reactive microglia are positive for HLA-DR in the substantia nigra of Parkinson's and Alzheimer's disease brains. Neurology. 1988;38:1285-1291.
32. Hirsch EC, Hunot S. Neuroinflammation in Parkinson's disease: a target for neuroprotection? Lancet Neurol. 2009;8:382-397.
33. Lee SJ. Origins and effects of extracellular alpha-synuclein:
implications in Parkinson's disease. J Mol Neurosci. 2008;34:17-22.
34. Brochard V, Combadiere B, Prigent A, Laouar Y, Perrin A, Beray-Berthat V, Bonduelle O, Alvarez-Fischer D, Callebert J, Launay JM, Duyckaerts C, Flavell RA, Hirsch EC, Hunot S. Infiltration of CD4+ lymphocytes into the brain contributes to neurodegeneration in a mouse model of Parkinson disease. J Clin Invest. 2009;119:182-192.
neurodegeneration and available means of protection. Front Biosci.
2008;13:3288-3311.
36. Skulachev VP. Mitochondrial physiology and pathology; concepts of programmed death of organelles, cells and organisms. Mol Aspects Med. 1999;20:139-184.
37. Mariani E, Polidori MC, Cherubini A, Mecocci P. Oxidative stress in brain aging, neurodegenerative and vascular diseases: an overview. J Chromatogr B Analyt Technol Biomed Life Sci. 2005;827:65-75.
38. Chan PH. Reactive oxygen radicals in signaling and damage in the ischemic brain. J Cereb Blood Flow Metab. 2001;21:2-14.
39. Doyle KP, Simon RP, Stenzel-Poore MP. Mechanisms of ischemic brain damage. Neuropharmacology. 2008;55:310-318.
40. Migliore L, Fontana I, Trippi F, Colognato R, Coppede F, Tognoni G, Nucciarone B, Siciliano G. Oxidative DNA damage in peripheral leukocytes of mild cognitive impairment and AD patients. Neurobiol Aging. 2005;26:567-573.
41. Mancuso M, Coppede F, Migliore L, Siciliano G, Murri L.
Mitochondrial dysfunction, oxidative stress and neurodegeneration. J Alzheimers Dis. 2006;10:59-73.
42. Lovell MA, Xie C, Markesbery WR. Decreased base excision repair and increased helicase activity in Alzheimer's disease brain. Brain Res.
2000;855:116-123.
43. Keller JN, Schmitt FA, Scheff SW, Ding Q, Chen Q, Butterfield DA, Markesbery WR. Evidence of increased oxidative damage in subjects with mild cognitive impairment. Neurology. 2005;64:1152-1156.
Zhou Y, Hong JS, Zhang J. Aggregated alpha-synuclein activates microglia: a process leading to disease progression in Parkinson's disease. FASEB J. 2005;19:533-542.
45. Lev N, Ickowicz D, Melamed E, Offen D. Oxidative insults induce DJ-1 upregulation and redistribution: implications for neuroprotection.
Neurotoxicology. 2008;29:397-405.
46. Leist M, Nicotera P. Apoptosis, excitotoxicity, and neuropathology.
Exp Cell Res. 1998;239:183-201.
47. Jacobson MD, Weil M, Raff MC. Programmed cell death in animal development. Cell. 1997;88:347-354.
48. Friedlander RM. Apoptosis and caspases in neurodegenerative diseases. N Engl J Med. 2003;348:1365-1375.
49. Rong Y, Distelhorst CW. Bcl-2 protein family members: versatile regulators of calcium signaling in cell survival and apoptosis. Annu Rev Physiol. 2008;70:73-91.
50. Berridge MJ. Calcium hypothesis of Alzheimer's disease. Pflugers Arch. 2010;459:441-449.
51. Dingledine R, Borges K, Bowie D, Traynelis SF. The glutamate receptor ion channels. Pharmacol Rev. 1999;51:7-61.
52. Mattson MP. Calcium and Free Radicals: Mediators of neurotrophic factor and excitatory transmitter-regulated developmental plasticity and cell death. Perspect Dev Neurobiol. 1996;3:79-91.
53. Schurr A. Neuroprotection against ischemic/hypoxic brain damage:
blockers of ionotropic glutamate receptor and voltage sensitive calcium channels. Curr Drug Targets. 2004;5:603-618.
trauma. Neuroscience. 2004;129:1021-1029.
55. Lipton SA. The molecular basis of memantine action in Alzheimer's disease and other neurologic disorders: low-affinity, uncompetitive antagonism. Curr Alzheimer Res. 2005;2:155-165.
56. Beal MF. Excitotoxicity and nitric oxide in Parkinson's disease pathogenesis. Ann Neurol. 1998;44:S110-114.
57. Mattson MP, Pedersen WA, Duan W, Culmsee C, Camandola S.
Cellular and molecular mechanisms underlying perturbed energy metabolism and neuronal degeneration in Alzheimer's and Parkinson's diseases. Ann N Y Acad Sci. 1999;893:154-175.
58. Johnson KA, Conn PJ, Niswender CM. Glutamate receptors as therapeutic targets for Parkinson's disease. CNS Neurol Disord Drug Targets. 2009;8:475-491.
59. Howells DW, Porritt MJ, Wong JY, Batchelor PE, Kalnins R, Hughes AJ, Donnan GA. Reduced BDNF mRNA expression in the Parkinson's disease substantia nigra. Exp Neurol. 2000;166:127-135.
60. Mogi M, Togari A, Kondo T, Mizuno Y, Komure O, Kuno S, Ichinose H, Nagatsu T. Brain-derived growth factor and nerve growth factor concentrations are decreased in the substantia nigra in Parkinson's disease. Neurosci Lett. 1999;270:45-48.
61. Gadjanski I, Boretius S, Williams SK, Lingor P, Knoferle J, Sattler MB, Fairless R, Hochmeister S, Suhs KW, Michaelis T, Frahm J, Storch MK, Bahr M, Diem R. Role of n-type voltage-dependent calcium channels in autoimmune optic neuritis. Ann Neurol.
2009;66:81-93.
phenytoin in experimental allergic encephalomyelitis. Neuroreport.
2002;13:1909-1912.
63. Sattler MB, Williams SK, Neusch C, Otto M, Pehlke JR, Bahr M, Diem R. Flupirtine as neuroprotective add-on therapy in autoimmune optic neuritis. Am J Pathol. 2008;173:1496-1507.
64. Simpkins JW, Yi KD, Yang SH, Dykens JA. Mitochondrial mechanisms of estrogen neuroprotection. Biochim Biophys Acta. 2009 65. Luna-Medina R, Cortes-Canteli M, Sanchez-Galiano S,
Morales-Garcia JA, Martinez A, Santos A, Perez-Castillo A.
NP031112, a thiadiazolidinone compound, prevents inflammation and neurodegeneration under excitotoxic conditions: potential therapeutic role in brain disorders. J Neurosci. 2007;27:5766-5776.
66. Verdonck O, Lahrech H, Francony G, Carle O, Farion R, Van de Looij Y, Remy C, Segebarth C, Payen JF. Erythropoietin protects from post-traumatic edema in the rat brain. J Cereb Blood Flow Metab.
2007;27:1369-1376.
67. Kaur C, Ling EA. Antioxidants and neuroprotection in the adult and developing central nervous system. Curr Med Chem.
2008;15:3068-3080.
73. 張介賓: 景岳全書, 台聯國風出版社, 台北市 1980;pp. 575.
74. 林珮琴: 類證治裁, 新文豐出版社, 台北 1999;pp. 239.
75. 王清任: 醫林改錯, 力行書局有限公司, 台北 2002;pp. 40-48.
76. 莊宏達: 節號本黃帝內經, 弘祥出版社, 台中 1993;pp. 345.
77. 莊宏達: 節號本黃帝內經, 弘祥出版社, 台中 1993;pp. 4-5.
78. 莊宏達: 節號本黃帝內經, 弘祥出版社, 台中 1993;pp. 172.
79. 王逸之: 金匱博詁, 台北 1984;pp. 64-66.
80. 孫思邈: 千金要方, 國立中醫藥研究所, 台北 1990;pp. 153.
81. 孫思邈: 華佗神醫秘傳, 笛藤出版圖書有限公司, 台北 1987;pp.
134.
82. 楊繼洲: 針灸大成, 人民衛生出版社, 北京 1995;pp. 1078.
83. 陳士鐸: 辨證錄, 人民衛生出版社, 北京 1996;pp. 241-242.
84. 郭 榮 . 血 管 性 痴 呆 的 中 醫 臨 床 進 展 . 遼 寧 中 醫 藥 大 學 學 報 . 2009;7:221-224.
85. 王懷隱: 太平聖惠方, 新文豐出版社, 台北 1978;pp. 245.
86. 莫霄雲. 中醫對輕度認知功能障礙的研究進展. 遼寧中醫藥大學
學報. 2009;11:219-220.
87. Liu J, Mori A. Antioxidant and free radical scavenging activities of Gastrodia elata Bl. and Uncaria rhynchophylla (Miq.) Jacks.
Neuropharmacology. 1992;31:1287-1298.
Hsieh CT. Anticonvulsive and free radical scavenging activities of Gastrodia elata Bl. in kainic acid-treated rats. Am J Chin Med.
2001;29:331-341.
89. Hsieh CL, Lin JJ, Chiang SY, Su SY, Tang NY, Lin GG, Lin IH, Liu CH, Hsiang CY, Chen JC, Ho TY. Gastrodia elata modulated activator protein 1 via c-Jun N-terminal kinase signaling pathway in kainic acid-induced epilepsy in rats. J Ethnopharmacol. 2007;109:241-247.
90. Hu JF, Li GZ, Li MJ. Protective effect of Gastrodia elata and E-gelatin on lead-induced damage to the structure and function of rat hippocampus. Zhonghua Lao Dong Wei Sheng Zhi Ye Bing Za Zhi.
2003;21:124-127.
91. Hu JF, Li GZ, Li MJ. The antagonistic action of Gastrodia elata combined with E-gelatin on lead-induced down regulation of c-fos expression in rat brain. Zhonghua Lao Dong Wei Sheng Zhi Ye Bing Za Zhi. 2003;21:128-131.
92. Horie S, Yano S, Aimi N, Sakai S, Watanabe K. Effects of hirsutine, an antihypertensive indole alkaloid from Uncaria rhynchophylla, on intracellular calcium in rat thoracic aorta. Life Sci. 1992;50:491-498.
93. Yano S, Horiuchi H, Horie S, Aimi N, Sakai S, Watanabe K. Ca2+
channel blocking effects of hirsutine, an indole alkaloid from Uncaria genus, in the isolated rat aorta. Planta Med. 1991;57:403-405.
94. Tang NY, Liu CH, Su SY, Jan YM, Hsieh CT, Cheng CY, Shyu WC, Hsieh CL. Uncaria rhynchophylla (miq) Jack plays a role in neuronal protection in kainic acid-treated rats. Am J Chin Med.
2010;38:251-263.
95. 李宗友. 三出延胡索中抗膽鹼脂酶和抗記憶缺失活性成分原阿片 碱. 國外醫學中醫中藥分冊. 2000;3:182.
96. Liao ET, Chiang SY, Lao CJ, Tang NY, Hsieh CT, Lin JG. Effect of Rhizoma Corydalis on focal cerebral infarct in ischemia-reperfusion injured rats. Acta Pharmacol Sin. 2001;22:1143-1148.
97. Yao XH, Li XJ. Protective effects and its mechanism of panaxatriol saponins isolated from Panax notoginseng on cerebral ischemia.
Zhongguo Zhong Yao Za Zhi. 2002;27:371-373.
98. 韓金安, 胡威夷, 孫增會. 顱腦損傷後鈣、鈣調蛋白的變化及三七 總皂苷的治療作用. 中國中西結合雜誌. 1999;19:227-229.
99. Jiang B, Bao YM, Li ZG. Protection by puerarin against MPP+
-induced neurotoxicity in PC12 cells mediated by inl1ibing mitochondrial dysfunction and caspase-3 一 like activavion. Neurosci Res. 2005;53:183-188.
100. Lo CJ, Lin JG, Kuo JS, Chiang SY, Chen SC, Liao ET, Hsieh CL.
Effect of salvia miltiorrhiza bunge on cerebral infarct in ischemia-reperfusion injured rats. Am J Chin Med. 2003;31:191-200.
101. Zhong YM, Nishijo H, Uwano T, Tamura R, Kawanishi K, Ono T. Red ginseng ameliorated place navigation deficits in young rats with hippocampal lesions and aged rats. Physiol Behav. 2000;69:511-525.
102. Cheng J, Kuang P, Wu W, Zhang F. Effects of transient forebrain ischemia and radix Salviae miltiorrhizae (RSM) on extracellular levels of monoamine neurotransmitters and metabolites in the gerbil
1999;19:135-140.
103. 秦泗明, 秦緒麗, 潘為法. 梗塞通治療缺血性中風 30 例 陜西中醫.
2003;2:131-132.
104. Leung AW, Mo ZX, Zheng YS. Reduction of cellular damage induced by cerebral ischemia in rats. Neurochem Res. 1991;16:687-692.
105. 賴真, 李麗珊, 程少冰. 黃耆和紅花對腦缺血再灌注後大鼠神經細 胞凋亡和天門冬氨酸特異性半胱氨酸蛋白酶 8 的影響. 中國動脈 硬化雜誌. 2008;11:885-888.
106. Han JQ, Li GC, Zhou XL. Influence of puerarin on cell apoptosis and bd neurotrophlc factor after cerebral ischemia in rats. Medical Journal of West China. 2009;1
107. 羅偉, 張新, 李桂金, 李保東, 馮小平. 葛根素治療急性腦梗塞的 臨床研究. 遼寧中醫雜誌 2000;27:212-213.
108. Wang YG. Parkinson s disease Total isoflavones from pueraria lobata P53 1-methyl-4-phenylpyridinium Apoptosis. Journal of Qiqihar Medical College. 2009;17
109. 張曉艷, 周鵬, 朱超, 楚向東. 三七、川芎對脊髓損傷后行為學變 化及軸突再生影響. 中國民族民間醫藥. 2009;20:4-5.
110. Zhao X, Ji X, Shi W, Wang P, Lui Z, Jin F. Impaction Chinese Traditional Medicinal Against Cerebral Ischemic/Reperfusion Injury.
Journal of Liaoning University of Traditional Chinese Medicine.
2009;10:172-173.
reduces cerebral infarct through its antioxidative and anti-inflammatory effects following transient focal cerebral ischemia in rats. Am J Chin Med. 2008;36:1105-1119.
112. Cheng CY, Su SY, Tang NY, Ho TY, Chiang SY, Hsieh CL. Ferulic acid provides neuroprotection against oxidative stress-related apoptosis after cerebral ischemia/reperfusion injury by inhibiting ICAM-1 mRNA expression in rats. Brain Res. 2008;1209:136-150.
113. Gao ZH, Huang KX, Xu HB. Protective effects of filavonoids in the roots of Scutellaria Baicalensis Geogi againt hydrogen peroxide-induced oxidative stress in SH-HY5Y cel1s. Pharmacol Res.
2001;43:173-178.
114. Li Y, Lu G, Zeng X, Yang H. Effect of Baicalin on Bax and Bcl-2 Expression in Striatum of Mice with Cerebral Ischemia-reperfusion Injury. Journal of Kunming Medical University. 2010;1:24-27.
115. 劉 文 泰 、 王 道 純 : 本 草 品 彙 精 要 , 南 天 書 局 , 台 北 1983;pp.
805-806.
116. 李時珍: 本草綱目, 新文豐出版公司, 1987;pp. 242-246.
117. Jacobs BP, Browner WS. Ginkgo biloba: a living fossil. Am J Med.
2000;108:341-342.
118. EGb 761: ginkgo biloba extract, Ginkor. Drugs R D. 2003;4:188-193.
119. Weitbrecht WU, Gmeiner HJ, Bocker F, Schult H. Blood sedimentation reaction in repeated dextran infusions in the therapy of cerebral infarct. Dtsch Med Wochenschr. 1985;110:977-978.
120. Rai GS, Shovlin C, Wesnes KA. A double-blind, placebo controlled
mild to moderate memory impairment. Curr Med Res Opin.
1991;12:350-355.
121. Mix JA, Crews WD. An Examination of the Efficacy of Ginkgo biloba Extract EGb 761 on the Neuropsychologic Functioning of Cognitively Intact Older Adults. Journal of Alternative & Complementary Medicine. 2000;6:219-229.
122. Hofferberth B. The effect of Ginkgo biloba extract on neurophysiological and psychometric measurement results in patients with psychotic organic brain syndrome. A double-blind study against placebo. Arzneimittelforschung. 1989;39:918-922.
123. Singh B, Song H, Liu XD, Hardy M, Liu GZ, Vinjamury SP, Martirosian CD. Dangshen (Codonopsis pilosula) and Bai guo (Gingko biloba) enhance learning and memory. Altern Ther Health Med. 2004;10:52-56.
124. Stough C, Clarke J, Lloyd J, Nathan PJ. Neuropsychological changes after 30-day Ginkgo biloba administration in healthy participants. The
124. Stough C, Clarke J, Lloyd J, Nathan PJ. Neuropsychological changes after 30-day Ginkgo biloba administration in healthy participants. The